This suggested that combination immunotherapy with anti-PD-1 and OAd-Siglec10-Fc significantly enhanced the suppression of tumor growth by activating multiple immune signaling pathways in the 4T1 tumor model. This evidence concerns the gene SIGLEC10 and neoplasm.